Robert W. Baird has recently initiated TransMedics Group Inc (TMDX) stock to Outperform rating, as announced on September 24, 2024, according to Finviz. Earlier, on August 21, 2024, Needham had initiated the stock to Buy, setting a price target of $208. Cantor Fitzgerald also initiated Overweight rating with a price target of $161. Additionally, Stephens initiated Overweight rating on June 4, 2024, with a target price of $151. Piper Sandler analysts, in their report published on March 28, 2024, also initiated Overweight rating and set a price target of $95 for TransMedics Group Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
TransMedics Group Inc (TMDX) Stock Trading Recap
On Tuesday, TransMedics Group Inc (TMDX) stock saw a decline, ending the day at $144.82 which represents a decrease of $-12.18 or -7.76% from the prior close of $157. The stock opened at $155 and touched a low of $144.34 during the day, reaching a high of $155.99. The volume of shares traded was 1.52 million exceeding the average volume of 0.95 million.
TMDX Stock Performance and Moving Averages
In recent trading, TransMedics Group Inc (TMDX) stock price has shown some volatility, fluctuating -7.17% over the last five trades and -13.83% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 99.42%, and it has plunged by -2.79% in the previous three months. Currently, TMDX is trading at -4.46%, -7.19%, and 23.83% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, TMDX, a Healthcare sector stock, is trading -18.35% below its 52-week high but remains 297.64% above its 52-week low. The Average True Range (ATR) (14 days) of 9.07 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
TransMedics Group Inc’s Profitability and Valuation Ratios
TransMedics Group Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 7.36% and a profit margin of 0.84%, with a gross margin of 99.42%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, TransMedics Group Inc’s market capitalization stands at $4.83 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 4056.58, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 75.36. Additionally, the Price-to-Sales Ratio is 13.47, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 25.41, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.40% of TransMedics Group Inc (TMDX)’s shares, while financial institutions hold 102.80%.
Notable insider trades include Hassanein Waleed H, President & CEO at TransMedics Group Inc (TMDX), who sold 8625 shares on Sep 16 ’24, at $153.42 each, totaling $1.32 million. On Sep 03 ’24, Khayal Tamer I, Chief Commercial Officer, sold 2960 shares for $159.6 each, amounting to $0.47 million. Additionally, on Aug 27 ’24, Corcoran Nicholas sold 10000 shares at $176.02 each, generating $1.76 million.
